# BIO-021 Clinical AI Post-Market Evidence & Drift Trace — Screen

- Date: 2026-08-26
- Status: `ABSORB INTO BIO-016`
- Business number: none
- Purpose: determine whether post-market/RWE/drift monitoring is a distinct PADIEM Bio product or a lifecycle input to BIO-016.

## Problem signal

2026 Korean support programmes explicitly fund the post-market side of digital medical-device commercialization, including post-market clinical work and real-world evidence generation for innovative-health-technology evaluation and health-insurance listing.

Relevant public signal:

- 2026 Digital Healthcare Medical Device Demonstration Support / K-MEDIhub: support for post-market clinical and real-world-evidence generation for innovative medical technology evaluation and health-insurance listing.
- Source: https://bizinfo.go.kr/sii/siia/selectSIIA200Detail.do?pblancId=PBLN_000000000118868

The underlying problem is real:

```text
approved / deployed medical AI
→ real-world population/site/workflow changes
→ performance or subgroup drift / incidents / new RWE
→ which existing claims, validation evidence and monitoring plans are still supportable?
→ what must be reviewed next?
```

## Current market / prior-art screen

This is not an empty category.

Examples:

- PROACTIVE-AI (2026 research dashboard) — FDA AI-device real-world performance / recall-risk and longitudinal monitoring.
- VarunaForge AI — independent continuous performance monitoring for AI-enabled medical devices, explicitly positioned around post-market evidence and drift.
- Mayo Clinic Platform — real-world data/analytics for device evidence generation, regulatory pathways and post-market surveillance.
- IQVIA — real-world-data-driven post-market surveillance for medical devices.
- Constat — FDA AI-device intelligence spanning post-market signals, recalls, disclosed drift and reimbursement pathways.

Representative sources:

- https://pmc.ncbi.nlm.nih.gov/articles/PMC13419582/
- https://varunaforge.com/
- https://www.mayoclinicplatform.org/focus-areas/medical-device/
- https://www.iqvia.com/-/media/iqvia/pdfs/library/white-papers/maximizing-post-market-surveillance-with-real-world-data.pdf
- https://constat.dev/

## Disposition

`KILL AS GENERIC STANDALONE`.

A generic product that says "monitor medical-AI drift and make RWE dashboards" would enter an already active category.

The useful PADIEM-specific remainder is instead a BIO-016 lifecycle trigger:

```text
post-market drift / subgroup shift / near miss / RWE finding
→ exact affected product/version
→ existing evidence inventory
→ potentially stale/scope-mismatched evidence
→ candidate revalidation/document review
→ RA/QA human decision
```

That is stronger because BIO-016 is not trying to become another telemetry/MLOps/RWE platform. It consumes a verified event or evidence signal and answers the narrower downstream question: **what existing regulated evidence must be reopened because of this event?**

## Portfolio boundary

- BIO-016 owns change/evidence/revalidation impact.
- BIO-015 can contribute clinical incident/site-replay events.
- BIO-018 remains the incident-replay function inside BIO-015.
- B48 supplies generic exact-version verification primitives.
- No new Business number.

## Final

```text
REAL_PROBLEM_SIGNAL = YES
GENERIC_MARKET_GAP = NO
PADIEM_NARROW_REUSE = YES
DISPOSITION = ABSORB_INTO_BIO_016
```
